Innovative Frontiers in Artemisinin Combination Therapy
Key Growth Drivers and Opportunities
Urgent Demand for More Effective Malaria Treatments: A major trend that runs the future of the market is required for more effective malaria remedies between persistent cases and increasing drug resistance. It is promoting innovation in ACT formulations to develop rapid acting, long lasting, and more patient -friendly options. With increased government and international health funding, this progress is improving access and distribution in malaria-sustainable regions, the situation serves as a central solution in the global fight against malaria and promotes strong market development.
Challenges
Artemisinin combination therapy (ACT) faces boundaries due to the emergence of artemisinin-resistant malaria strains in the market, especially in parts of Southeast Asia. Additionally, inconsistent supply chains, high dependence on donor funding, and limited healthcare infrastructure in some spatial regions obstruct wide access. The need for constant innovation to be ahead of regulator challenges and resistance also leads to the ongoing obstacles for market stability and development.
Innovation and Expansion
Breakthrough A Treatment for Malaria Without Artemisinin Gives Children Hope
In November 2024, Positive findings from KALUMI, a Phase 2 study of a new, non-artemisinin malaria medication combination being developed with Novartis and MMV, have been announced by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium. Given that partial resistance to artemisinin derivatives throughout Africa jeopardizes efforts to eradicate the illness, this is a significant advancement in the fight against malaria.
The effectiveness and safety of a combination of lumefantrine, reformulated for once-daily dosage, and ganaplacide, a new drug, were assessed in the KALUMI trial. This novel combination was tested against artemether-lumefantrine, the most popular artemisinin-based combination therapy (ACT) for treating uncomplicated malaria in Africa.
Fosun Pharma Acquires USD 3.5M to Promote the Development of Malaria Treatments
In December 2023, The Japanese Global Health Innovative Technology (GHIT) Fund has awarded Y500m (USD 3.3m) to China-based Fosun Pharma to further the development of a triple artemisinin combination medication for the treatment of malaria. Artemether, lumefantrine, and amodiaquine are the three antimalarial medications that make up the triple artemisinin combination medication, which comes in a fixed dosage format.
The money used to support the Phase III research that looks into the combo treatment. Fosun, the Japanese investment firm Marubini, the Thailand-based research partnership of the universities Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV) will all work together to undertake the III trial.
Novartis Provides One Billion Antimalarial Treatment Courses Globally
In May 2021, Novartis declared that since 1999, it has provided one billion antimalarial therapy sessions. Over 90% of this artemisinin-based combination treatment (ACT) was given to malaria-endemic nations worldwide at no profit.
The most lethal kind of malaria, P. falciparum, which accounts for more than 99% of cases in Africa and half of those in Asia, is treated with ACTs as the standard of care2. ACTs have revolutionized the treatment of malaria since the turn of the century and helped to significantly lower the number of malaria-related fatalities.
Inventive Sparks, Expanding Markets
Among the leading companies for artemisinin combination therapy are Novartis AG, Cipla, Bliss GVS, and KPC Pharmaceuticals, Inc. The artemisinin combination therapy (ACT) firm is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat medication resistance, and improve patient compliance.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
10 hours ago
- CNBC
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
CNBC
10 hours ago
- CNBC
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That includes 100% growth in the U.S. It follows a 56% increase in Kisqali sales in the first quarter to March. Speaking on an earnings call, CEO Vas Narasimhan said Kisqali was the drug with the greatest scope for outperformance. Global breast cancer diagnoses and deaths are projected to increase by 2050, according to the World Health Organization's cancer agency, with 1 in 20 women worldwide expected to be diagnosed with breast cancer in their lifetime. That could translate to 3.2 million new cases and 1.1 million deaths a year worldwide by 2050 if current trends continue, the study found — significantly higher than 2022's 2.3 million new cases and 670,000-related deaths. Narasimhan also cited Novartis' "strong pipeline" of other drugs, including its Pluvicto prostate cancer treatment and Scemblix for chronic myeloid leukemia, which he said was also "on track to be a blockbuster." "We continue to drive strong performance on our ongoing launches for Kisqali, Pluvicto, and Scemblix, demonstrating the replacement power in our portfolio," he added in a statement accompanying the results. The comments come as Novartis seeks to shake its reliance on its top-selling Entreso heart failure drug, which faces U.S. patent expiry next year. Entresto brought in $7.8 billion in 2024, accounting for around 15% of the company's overall global sales. It said Thursday that it expects generic drug makers to begin producing copycat versions of the drug by mid-2025, although that timeline is "subject to ongoing IP [intellectual property] and regulatory litigation." On Wednesday, a U.S. federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the drug before the patent expires. Sales of Entresto rose 22% in the second quarter, in line with the prior three-month period. "Short-term it's an important product for us," outgoing chief financial officer Harry Kirsch said of Entresto Thursday. "We have IP that we're defending. Should we be successful in further defending our appeal, each month we'll have some nice significant upside," he added. Overall, Novartis' second-quarter net sales rose 11% on a constant currency basis to $14.05 billion, just shy of the $14.18 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating income, meanwhile, rose 21% to $5.93 billion, slightly above the $5.69 billion expected. Novartis said it now expects full-year core operating income to grow by "low teens," up from "low double-digit" previously, while it retained its forecast for sales growth in the high single digits. The company also announced an up to $10 billion share buyback, citing "confidence" in its mid- and long-term growth.
National Geographic
13 hours ago
- National Geographic
Malaria
Anopheles Mosquito Her abdomen full of blood that will nourish her eggs, a femaleAnopheles mosquito takes to the air. Her next landing may be a dangerous one—for the human who receives her bite. The female Anopheles mosquito is the only insect capable of carrying the human malaria parasite. Photograph by Hugh Sturrock Learn about the mosquito-transmitted disease, which kills over one million per year, most of them children. The disease chiefly affects lowland tropical regions, where conditions favor Anopheles mosquitoes, which carry the malaria parasite plasmodium. It's the blood-seeking females that inject these microscopic invaders, each bite acting like an infected hypodermic needle. Of the four kinds of plasmodia, Plasmodium falciparum is by far the most dangerous, responsible for about half of all malaria cases and 95 percent of deaths. Parasite The parasite has a complicated life cycle, which begins in the mosquito's gut before moving to the salivary glands, where it awaits transfer to the next host. Once in a human's bloodstream, the parasite lodges in the liver, burrowing into cells where it feasts and multiplies. After a week or two the plasmodia burst out—around 40,000 replications for each parasite that entered the body. Next they target red blood cells, this time repeatedly, until there are billions of parasites in circulation. If this cycle isn't checked, the body starts to fail, because with so many oxygen-carrying red cells being destroyed there are too few left to sustain vital organs. Meanwhile, all it takes for the parasite to pass on its grim legacy is for another mosquito to stop off for a meal. Almost two-thirds of humans infected live in sub-Saharan Africa, which also bears around 90 percent of the global malaria death toll. A child there dies from the disease about every 30 seconds. Elsewhere, countries worst affected are in southern Asia and Latin America. Those most vulnerable are young children, who have yet to develop any resistance to the disease, and pregnant women who have reduced immunity. Signs of infection include flu-like symptoms such as fever, shivering, headache, and muscle ache. The P. falciparum parasite can lead to life-threatening conditions such as brain damage (cerebral malaria), severe anemia, and kidney failure. Survivors are often left with permanent neurological damage. For centuries the only widely known malaria remedy was quinine, which came from the bark of the cinchona tree of Peru and Ecuador. Then, in the 1940s, a synthetic drug was created using the compound chloroquine. Around the same time, the insecticide known as DDT was developed. These twin weapons led to a worldwide assault on malaria, eradicating the disease in many areas, including the United States and southern Europe. But malaria has made a major comeback since the 1970s, partly because DDT use was severely restricted after it was found to be harmful to certain wildlife, and because the plasmodium parasite started becoming resistant to anti-malaria drugs. With more people now falling sick from malaria than ever before, the need to tackle it has never been so urgent. The top priority, health experts say, is finding a vaccine—seen as the only surefire way of beating the disease. Peekaboo American mosquito nets (left) afforded explorers better vision and ventilation than English ones (right). That's according to the 1926 National Geographic article in which this photo appeared, which chronicled an exploration of the Amazon Valley. Photograph by Albert W. Stevens, Nat Geo Image Collection
